Bryan Johnson reports advanced meibomian gland dysfunction och a 4-treatment eye protocol

On 18 augusti 2026, Bryan Johnson reported a new eye diagnosis och treatment series. He says an ophthalmologist, Dr Amir Moarefi, found advanced meibomian gland dysfunction (MGD), tear production under 10 mm i 5 minutes i both eyes, och substantial meibomian-gland dropout on infrared meibography. He links the condition till evaporative dry eye och concurrent aqueous deficiency. The intervention bundle combines intense pulsed light, radiofrequency, manual gland expression, intraductal probing, och 630 nm low-level light therapy. He also reports warm compresses, preservative-free och lipid-replacement drops, prescription anti-inflammatory drops, a compounded azithromycin spray, moisture-chamber glasses, tear stimulation, omega-3, och lutein. Johnson says imaging showed a 30% improvement i gland function, with less irritation och less resistance during probing. The design has no control condition, no prespecified primär endpoint, no independent assessor, och several treatments started together. He therefore cannot identify which component produced the change. The post labels intraductal probing as experimental och describes future plans involving androgen, growth-factor, or organoid approaches that have not been testad i humans. This is a detailed n=1 medical report, not evidens that the combined protocol reverses gland loss or dry eye i other personer. The reported tear values och imaging results need clinical records och repeat measurements for independent assessment.

Given that I did four therapies at the same time: IPL, RF, probing, och low level light therapy, I can’t determine which therapy did what.